OGN News and Press, Organon & Co.

VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...

2024-07-17 10:00:00 ET Summary Bristol-Myers Squibb stock has performed poorly and analysts have started to downgrade its rating citing a 'value trap'. Value traps have all shared a similar set of problems, which don't apply to Bristol-Myers Squibb. The company is facing a ste...

Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...

2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...

2024-05-30 16:50:22 ET Summary SPDR® S&P 600 Small Cap Value ETF combines two of the three factors of the original Fama-French model: value and size. The SLYV ETF is well-diversified across holdings, but overweight in financials. SLYV performance and risk metrics sinc...

2024-05-28 10:30:08 ET Summary WisdomTree U.S. SmallCap Dividend Fund holds about 600 small and micro cap stocks weighted based on dividends. DES is heavy in financials, but well diversified across holdings. DES' valuation, quality and 12-month return are fine, but its histori...

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14, an investigational Prolia ® and Xgeva ® (denosumab) biosimilar. Denosumab has been a...

2024-05-23 02:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-11 06:58:33 ET Summary Organon, Pfizer, and Bristol Myers all offer yields above 5% and can  compete with most Treasuries, but only Organon is up YTD. Spinoffs often struggle in their initial years, but Organon's partial reversal of its decline since Merck's castoff h...

2024-05-09 08:15:00 ET Summary Teva Pharmaceutical stock has been trending higher since October 2023, closing at nearly $16.00. The company reported strong first-quarter results, with increased revenue and growth in key metrics. Teva has a positive business outlook for 2024, w...